Bayer’s pharma sales will “remain stable” through 2026, division chief Stefan Oelrich, said during the ... toughest year for our turnaround,” CEO Bill Anderson said. The reduction is ...
Bayer chief executive Bill Anderson has followed ... Both will report to pharma division president Stefan Oelrich, who remains in post, as does Christian Rommel, head of pharma R&D, and Holger ...
Bayer now says it expects to make €3 ... clinical trials in other potential indications," said Bayer's pharma chief Stefan Oelrich. That includes a second phase 3 trial in metastatic hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback